- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03466827
Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma (TET-SEL)
A Phase II Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumour (TET) Progressing After Primary Chemotherapy.
The aim of the study is to determine the efficacy of selinexor in adults with TETs determined by overall response rate (RECIST 1.1) in two parallel cohorts of patients with advanced thymomas or thymic carcinomas. The study is an international, multicenter, open label phase II trial using Simons two stage design. The study population is adults with histologically confirmed, advanced, inoperable TETs who are progressing after treatment with least one platinum containing chemotherapy regimen.
This study is comprised of 2 similar phase II tirals, one running in EU (25 patients) and one running in US (25 patients).
There are two study arms:
Arm A: Thymoma
- Stage 1: 15 patients
- Stage 2: 10 patients
Arm B: Thymic carcinoma
- Stage 1: 15 patients
- Stage 2: 10 patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Morten Mau-Soerensen, MD, PhD
- Phone Number: +45 3545 0879
- Email: paul.morten.mau-soerensen@regionh.dk
Study Contact Backup
- Name: Kristoffer S Rohrberg, MD, PhD
- Phone Number: +45 3545 6353
- Email: kristoffer.staal.rohrberg@regionh.dk
Study Locations
-
-
-
Copenhagen, Denmark, 2100
- Recruiting
- Rigshospitalet
-
Contact:
- Kristoffer S Rohrberg, MD, PhD
- Phone Number: +45 3545 6353
- Email: kristoffer.staal.rohrberg@regionh.dk
-
Contact:
- Morten Mau-Soerensen, MD, PhD
- Phone Number: + 45 3545 0879
- Email: morten.mau-soerensen@regionh.dk
-
Principal Investigator:
- Gedske Daugaard, Professor
-
-
-
-
-
Lyon, France
- Not yet recruiting
- Hospices Civils de Lyon
-
Contact:
- Marylise Ginoux, Professor
- Email: marylise.ginoux@chu-lyon.fr
-
Principal Investigator:
- Marylise Ginoux, Professor
-
Paris, France
- Not yet recruiting
- Intitut Curie
-
Contact:
- Nicolas Girard, Professor
- Email: nicolas.girard2@curie.fr
-
Principal Investigator:
- Nicolas Girard, Professor
-
Paris, France
- Not yet recruiting
- Intitut Gustave Roussy
-
Contact:
- Benjamin Besse, Professor
- Email: benjamin.besse@gustaveroussy.fr
-
Principal Investigator:
- Benjamin Besse, Professor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed advanced TET (thymoma or thymic carcinoma)
- Inoperable per local Investigator (Masaoka Stage III or IV)
- Progression after treatment with least one platinum containing chemotherapyregimen
- Measurable disease (RECIST 1.1)
- Age ≥18 years
- ECOG PS <2
- Patients must have recovered from the toxic effects of prior therapy at the time of initiation of the study drug unless toxicity is stable.
- A 4 weeks interval from any investigational agents or cytotoxic chemotherapy to start of study is required
- Signed informed consent
Adequate bone marrow function and organ function:
- Hematopoietic function: total white blood cell count (WBC) ≥ 3000/mm³, absolute neutrophil count (ANC) ≥ 1500/mm³, platelet count ≥ 100,000/mm²
- Hepatic function: bilirubin < 1.5 times the upper limit of normal (ULN), ALT < 2.5 times ULN or ALT < 5.0 times ULN in the presence of liver metastases
- Creatinine clearance > 30 ml/min according to Cockcroft-Gault
- Patients of childbearing potential must agree to use adequate birth control during and for 3 months after participation in this study
Exclusion Criteria:
No significant medical illness that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy, including
- Unstable cardiovascular function
- Known active hepatitis A, B, or C infection; or known to be positive for HCV RNA or HBsAg (HBV surface antigen)
- Markedly decreased visual acuity
- Active infection requiring intravenous antibiotics
- Pregnancy or breast-feeding
- Symptomatic brain metastasis requiring corticosteroids
- Uncontrolled autoimmune disorders. Patients with autoimmune disorders under control on medication may be included. Patients with pure red cell aplasia may be included if haemoglobin levels are relatively stable on transfusions or medication
- Any other cancer (excluding radically operated localised squamous skin cancer) with clinical activity within the last 2 years
- Significantly diseased or obstructed gastrointestinal tract, malabsorption, uncontrolled vomiting or diarrhea or inability to swallow oral medications
- No dehydration of NCI-CTCAE grade ≥ 1
- Serious psychiatric or medical conditions that could interfere with treatment.
- No history of organ allograft
- No concurrent therapy with approved or investigational anticancer therapeutics
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate
Time Frame: 24 months
|
To determine the overall response rate according to RECIST 1.1
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival
Time Frame: 6 months
|
To determine six months progression free survival of patients with TET treated with selinexor
|
6 months
|
Adverse Events
Time Frame: 24 months
|
The number of adverse events as determined by Common Terminology Criteria for Adverse Events (CTCAEs) version 4.03
|
24 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Morten Mau-Soerensen, MD, PhD, Rigshospitalet, Denmark
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TET-SEL
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thymoma
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage III Thymoma AJCC v8 | Stage IIIA Thymoma AJCC v8 | Stage IIIB Thymoma AJCC v8 | Stage IV Thymoma AJCC v8 | Stage IVA Thymoma AJCC v8 | Stage IVB Thymoma AJCC v8 | Unresectable Thymic CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedInvasive Thymoma and Thymic Carcinoma | Recurrent Thymoma and Thymic Carcinoma | Stage III Thymoma | Stage IVA Thymoma | Stage IVB ThymomaUnited States
-
Tiziana Life Sciences LTDTerminatedMalignant ThymomaUnited States, Italy
-
Yale UniversityWithdrawn
-
Prof. Dr. Berthold SchalkeCrolll GmbhCompletedPrimary Inoperable Thymoma | Local Recurrent ThymomaGermany
-
Tang-Du HospitalRecruitingThymoma and Thymic CarcinomaChina
-
Peng LiuNot yet recruitingHistological or Cytological Confirmed Stage Ⅲ and Ⅳa ThymomaChina
-
Armando Santoro, MDCompletedThymoma and Thymic CarcinomaItaly
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...RecruitingThymic Carcinoma | Type B3 ThymomaItaly
-
Fudan UniversityRecruitingThymoma and Thymic CarcinomaChina
Clinical Trials on Selinexor
-
Karyopharm Therapeutics IncBelgium and Luxembourg Gynaecological Oncology Group; North-Eastern German... and other collaboratorsActive, not recruitingEndometrial CancerUnited States, China, Israel, Spain, Belgium, Germany, Greece, Czechia, Italy, Canada
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Rhabdoid Tumor | Wilms Tumor | Nephroblastoma | Malignant Peripheral Nerve Sheath Tumors | MPNST | XPO1 Gene MutationUnited States
-
The First Hospital of Jilin UniversityRecruitingPTCL Patients Who Achieved Complete Response From Frontline TreatmentChina
-
University of RochesterKaryopharm Therapeutics IncRecruitingSmoldering Multiple MyelomaUnited States
-
Karyopharm Therapeutics IncGOG Foundation; European Network of Gynaecological Oncological Trial Groups... and other collaboratorsRecruitingEndometrial CancerUnited States, Belgium, Spain, Israel, Australia, Italy, Georgia, Ireland, Greece, Slovakia, Canada, Hungary, Czechia
-
University of UtahKaryopharm Therapeutics IncActive, not recruitingPrimary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia MyelofibrosisUnited States
-
Karyopharm Therapeutics IncCompletedHematological MalignanciesUnited States, Denmark, Canada
-
Karyopharm Therapeutics IncTerminatedRichter's TransformationUnited States, Germany, United Kingdom, Spain, Poland
-
Chunrui LiNanjing IASO Biotherapeutics Co.,LtdRecruitingExtramedullary Multiple MyelomaChina
-
Karyopharm Therapeutics IncRecruitingDiffuse Large B-cell LymphomaUnited Kingdom, United States, Australia, Austria, Belgium, Bulgaria, Canada, France, Germany, Greece, Hungary, India, Israel, Italy, Netherlands, New Zealand, Poland, Serbia, Spain